Top Performing Drug – Ozempic (September Edition)

Shots: PharmaShots’ next episode on the top-performing drug of the month, based on 2021 revenue, focuses on Ozempic, a drug developed and marketed by Novo Nordisk Ozempic (semaglutide) is a human GLP-1 receptor agonist (or GLP-1 analog). It, when taken along with diet and exercise, is proven to improve blood sugar in adults with type 2…

BySenior EditorSeptember 27, 2023

TOP 20

Top 20 Oncology Companies Based on 2022 By Total Revenue

Shots: With more than 50% of ongoing clinical trials worldwide in oncology domains, cancer remains one of the leading causes of death worldwide. Oncology companies are steadfastly looking for innovative therapies to cure both hematologic and solid tumor cancer The global oncology drug market size in 2022 was valued at $185B and is forecasted to…

ByPrince GiriSeptember 13, 2023

VIEWPOINTS

Dr. Christopher Piorkowski Shares His Views on the US FDA Approval of TactiFlex Ablation Catheter to Treat Abnormal Heart Rhythm

Shots: Christopher started by highlighting the working of the TactiFlex Ablation Catheter and how it can be used for the treatment of patients with Atrial Fibrillation He also talked about the study design and the key findings from the TactiFlex AF IDE trial. He later gave a comparative view of the TactiFlex catheter vs. conventional…

BySenior EditorSeptember 11, 2023

INSIGHTS+

Top Performing Drug – Ibrance (August Edition)

Shots: In continuation of our previous series on the top-performing drug of the month, based on 2021 revenue, this month we have selected Ibrance and prepared a curated analysis report for our readers Ibrance is a targeted cancer therapy developed to treat certain types of advanced breast cancer. It belongs to a class of drugs called CDK4/6…

BySenior EditorAugust 23, 2023

INSIGHTS+

New Drug Designations – July 2023

Shots: PharmaShots' designation report provides a concise overview of several drugs and their designations by the US FDA, the EU, China, and Korea. This month’s report includes 7 biological drugs, 10 small molecules, 8 cell and gene therapies, 1 radiopharmaceutical, 2 microbiota and 1 diagnostic test MyoPax’ Satori-01, focused on repairing the Exstrophy-Epispadias Complex sphincter…

BySenior EditorAugust 21, 2023

INSIGHTS+

Disease of the Month – Spinal Muscular Atrophy

Shots: To keep our readers acquainted with several disease conditions, ongoing trials, and available treatment options, PharmaShots brings every month a detailed take on a particular disease after thorough research Continuing the series for the disease of the month, PharmaShots brings this month a summary of Spinal Muscular Atrophy, a genetic neuromuscular disease that affects…

BySaurabh ChaubeyAugust 17, 2023

INSIGHTS+

Top Performing Drug – Ocrevus (July Edition)

Shots: In continuation of our previous series on the top-performing drug of the month, based on 2021 revenue, we bring for our readers a concise yet thorough analysis of the drug Ocrevus Ocrevus is a prescription medicine used to treat adults with relapsing or primary progressive multiple sclerosis including CIS, RRMS, and SPMS PharmaShots presents…

BySenior EditorJuly 26, 2023

INSIGHTS+

Top Performing Drug – Enbrel (June Edition)

Shots: In continuation of our previous series on the top-performing drug of the month, based on 2021 revenue, this month we have covered Enbrel as the top-performing drug of the month Enbrel is a biologic drug classified as a TNF inhibitor used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and other autoimmune diseases PharmaShots…

BySenior EditorJune 28, 2023

INSIGHTS+

Top Performing Drug – Trikafta/Kaftrio (May Edition)

Shots: In continuation of our previous series on the top-performing drug of the month, based on 2021 revenue, this month we have covered Trikafta/Kaftrio as the top-performing drug of the month Trikafta is a combination of ivacaftor, tezacaftor, and elexacaftor indicated for the treatment of cystic fibrosis in pediatric patients who have at least one…

BySenior EditorMay 24, 2023

VIEWPOINTS

Dr. Harmony Garges, CMO at ViiV Healthcare, Shares Insights on Positive Findings from the SOLAR Study of Cabenuva

Shots: Dr. Harmony gave the details about the positive 12-month findings from the P-IIIb SOLAR trial of the first and only complete long-acting injectable regimen Cabenuva vs. Biktarvy She also talked about the comparison of the Cabenuva regimen with the other existing & developing products for HIV including the Biktarvy regimen The interview gives an…

BySenior EditorMay 18, 2023

Top Performing Drug – Ozempic (September Edition)

Top 20 Oncology Companies Based on 2022 By Total Revenue

Dr. Christopher Piorkowski Shares His Views on the US FDA Approval of TactiFlex Ablation Catheter to Treat Abnormal Heart Rhythm

Top Performing Drug – Ibrance (August Edition)

New Drug Designations – July 2023

Disease of the Month – Spinal Muscular Atrophy

Top Performing Drug – Ocrevus (July Edition)

Top Performing Drug – Enbrel (June Edition)

Top Performing Drug – Trikafta/Kaftrio (May Edition)

Dr. Harmony Garges, CMO at ViiV Healthcare, Shares Insights on Positive Findings from the SOLAR Study of Cabenuva

Contact US

FOLLOW US